Sihuan Pharmaceutical Holdings Group Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Sihuan Pharmaceutical Holdings Group.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 10.9% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
What Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 25% Share Price Gain Is Not Telling You
Oct 02
Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt?
Sep 30Here's Why It's Unlikely That Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO Will See A Pay Rise This Year
May 31Investors Still Waiting For A Pull Back In Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
May 27A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Dec 05Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?
Oct 31Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Aug 19Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Apr 21Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Worth HK$0.8 Based On Its Intrinsic Value?
Nov 03Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Oct 11Is There An Opportunity With Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 34% Undervaluation?
Jun 21Estimating The Intrinsic Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Mar 09A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Nov 28Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly
Sep 26We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO For Now
Jun 22How Does Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Fare As A Dividend Stock?
May 11Sihuan Pharmaceutical Holdings Group's (HKG:460) Shareholders May Want To Dig Deeper Than Statutory Profit
Mar 30How Much Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Do Insiders Own?
Mar 07Should You Buy Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) For Its Dividend?
Feb 07
Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Jan 11Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Dec 21Why Sihuan Pharmaceutical Holdings Group's (HKG:460) CEO Pay Matters
Dec 07In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sihuan Pharmaceutical Holdings Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2024 | 1,755 | -38 | -40 | 208 | N/A |
| 3/31/2024 | 1,808 | -46 | -68 | 204 | N/A |
| 12/31/2023 | 1,861 | -54 | -96 | 199 | N/A |
| 6/30/2023 | 1,773 | -2,041 | -697 | -300 | N/A |
| 3/31/2023 | 1,977 | -1,996 | -620 | -127 | N/A |
| 12/31/2022 | 2,181 | -1,951 | -543 | 46 | N/A |
| 6/30/2022 | 2,595 | -144 | -306 | 425 | N/A |
| 3/31/2022 | 2,817 | 141 | -183 | 545 | N/A |
| 12/31/2021 | 3,038 | 427 | -60 | 665 | N/A |
| 9/30/2021 | 3,304 | 681 | 63 | 740 | N/A |
| 6/30/2021 | 3,317 | 945 | 187 | 815 | N/A |
| 3/31/2021 | 2,891 | 727 | -83 | 521 | N/A |
| 12/31/2020 | 2,464 | 508 | -353 | 227 | N/A |
| 9/30/2020 | 2,370 | -14 | -429 | 214 | N/A |
| 6/30/2020 | 2,275 | -537 | -504 | 200 | N/A |
| 3/31/2020 | 2,577 | -1,623 | 162 | 809 | N/A |
| 12/31/2019 | 2,878 | -2,709 | 828 | 1,418 | N/A |
| 9/30/2019 | 3,088 | -1,927 | 1,238 | 1,726 | N/A |
| 6/30/2019 | 3,297 | -1,144 | 1,647 | 2,033 | N/A |
| 3/31/2019 | 3,107 | 238 | 1,525 | 1,913 | N/A |
| 12/31/2018 | 2,917 | 1,620 | 1,403 | 1,793 | N/A |
| 9/30/2018 | 2,751 | 1,496 | 1,481 | 1,906 | N/A |
| 6/30/2018 | 2,584 | 1,372 | 1,559 | 2,019 | N/A |
| 3/31/2018 | 2,665 | 1,411 | N/A | 1,968 | N/A |
| 12/31/2017 | 2,746 | 1,449 | N/A | 1,918 | N/A |
| 9/30/2017 | 2,992 | 1,632 | N/A | 1,889 | N/A |
| 6/30/2017 | 3,238 | 1,815 | N/A | 1,860 | N/A |
| 3/31/2017 | 3,212 | 1,761 | N/A | 1,939 | N/A |
| 12/31/2016 | 3,186 | 1,708 | N/A | 2,018 | N/A |
| 9/30/2016 | 2,984 | 1,528 | N/A | 2,037 | N/A |
| 6/30/2016 | 2,781 | 1,347 | N/A | 2,056 | N/A |
| 3/31/2016 | 2,974 | 1,705 | N/A | 1,812 | N/A |
| 12/31/2015 | 3,167 | 2,062 | N/A | 1,569 | N/A |
| 9/30/2015 | 3,321 | 2,181 | N/A | 1,691 | N/A |
| 6/30/2015 | 3,474 | 2,299 | N/A | 1,813 | N/A |
| 3/31/2015 | 3,279 | 1,985 | N/A | 1,787 | N/A |
| 12/31/2014 | 3,084 | 1,671 | N/A | 1,761 | N/A |
| 9/30/2014 | 2,365 | 1,581 | N/A | 1,650 | N/A |
| 6/30/2014 | 1,645 | 1,491 | N/A | 1,538 | N/A |
| 3/31/2014 | 2,116 | 1,388 | N/A | 1,556 | N/A |
| 12/31/2013 | 2,586 | 1,285 | N/A | 1,574 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 460's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if 460's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 460's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 460's revenue is forecast to grow faster than the Hong Kong market.
High Growth Revenue: Insufficient data to determine if 460's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 460's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 03:08 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sihuan Pharmaceutical Holdings Group Ltd. is covered by 24 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shaojing Tong | BofA Global Research |
| Harry He | China Galaxy International Securities (Hong Kong) |
| Sze Chuen Tam | Core Pacific -Yamaichi International (H.K.) Limited |